Halozyme Therapeutics, Inc. Earnings

Halozyme Therapeutics, Inc.’s revenue jumped 51.6% since last year same period to $451.77Mn in the Q4 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated 27.52% jump in its revenue since last 3-months.

Halozyme Therapeutics, Inc.’s net profit fell -203.34% since last year same period to $-141.59Mn in the Q4 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -180.81% fall in its net profits since last 3-months.

Halozyme Therapeutics, Inc.’s net profit margin fell -168.17% since last year same period to -31.34% in the Q4 2025. On a quarterly growth basis, Halozyme Therapeutics, Inc. has generated -163.37% fall in its net profit margins since last 3-months.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current quarter stand at 1.76 - a -7.37% fall from last quarter’s estimates.

Halozyme Therapeutics, Inc.’s earning per share (EPS) estimates for the current year stand at 1.76.

Halozyme Therapeutics, Inc.’s earning per share (EPS) fell -100% since last year same period to 0 in the Q1 2026. This indicates that the Halozyme Therapeutics, Inc. has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.